EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma

Veronica Guglielmana iD, Francesco Maria Fusi, Valentina Giardini, Federica Cocito, Carlo Gambacorti-Passerini iD

Hematological Oncology · 2025

DOI: 10.1002/hon.70038 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hematological Oncology, 2025. Verfasst von Veronica Guglielmana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. Hauptthemen laut MEDLINE: Crizotinib, Lymphoma, Large-Cell, Anaplastic, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) typically affects young individuals and, despite high responsiveness to cytotoxic drugs, relapses occur in over 50% of patients. Crizotinib has improved outcomes, but its management in patients desiring parenthood remains an issue. This study presents the first description of four successful pregnancies during crizotinib treatment for ALK+ALCL: a female patient achieving two pregnancies through assisted reproductive technologies (ART), temporarily discontinuing crizotinib and maintaining a complete remission (CR), and a male patient conceiving naturally while on continuous therapy. These cases demonstrate crizotinib potential to support conception without compromising disease control, even in the absence of specific guidelines on treatment discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CrizotinibLymphoma, Large-Cell, AnaplasticProtein Kinase InhibitorsAntineoplastic AgentsHumansFemalePregnancyAnaplastic Lymphoma KinaseAdultMale

Stichwörter der Autor:innen

aggressive non‐Hodgkin's lymphomalymphoproliferative disorderspregnancyquality of life

Substanzen

CrizotinibAnaplastic Lymphoma KinaseProtein Kinase InhibitorsALK protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Hematology Division and Bone Marrow Unit, IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Department of Maternal Fetal and Pediatric Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Obstetrics Unit, Department of Maternal Fetal Medicine, IRCCS San Gerardo dei Tintori, Monza, Italy.

ORCID-Profile: Veronica Guglielmana, Carlo Gambacorti-Passerini

Zitieren

APA

Guglielmana, V., Fusi, F. M., Giardini, V., Cocito, F., & Gambacorti-Passerini, C. (2025). Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70038

Vancouver

Guglielmana V, Fusi FM, Giardini V, Cocito F, Gambacorti-Passerini C. Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70038

BibTeX
@article{Guglielmana2025,
  author = {Guglielmana, Veronica and Fusi, Francesco Maria and Giardini, Valentina and Cocito, Federica and Gambacorti-Passerini, Carlo},
  title = {Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70038}
}
Kostenlos starten →